ReviewOncoTargets and therapy2026

Efficacy and Safety of Regorafenib with or without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Systematic Review and Arm-Level Synthesis of Real-World Comparative Cohorts.

Xinlin Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.